Keyphrases
Randomized Placebo-controlled Trial
100%
Varicella Vaccine
100%
Haemopoietic Stem Cell Transplantation
100%
Stem Cell Transplant Recipients
100%
Placebo Groups
87%
Herpes Zoster
87%
Placebo
50%
Risk Difference
37%
Adverse Events
25%
Transplantation
25%
One Dose
25%
Phase II Trial
25%
Vaccine Effectiveness
25%
Success Criteria
25%
Efficacy Endpoint
25%
Hazard Ratio
12%
South Asia
12%
Serious Adverse Events
12%
Associated Complications
12%
Transplant Center
12%
Placebo-controlled
12%
North America
12%
Stem Cell Transplantation
12%
Opportunistic Infections
12%
South America
12%
Combination Vaccine
12%
Peri
12%
EudraCT
12%
Merck
12%
Inactivated Vaccine
12%
Exclusion Criteria
12%
Relative Reduction
12%
Whole-cell Vaccine
12%
First Dose
12%
Varicella Zoster Virus
12%
Antiviral Prophylaxis
12%
Statistician
12%
Early Vaccination
12%
Second Dose
12%
Follow-up Data
12%
Herpes Zoster Infection
12%
Adjudication
12%
Laboratory Workers
12%
Medical Center
12%
Injection Site
12%
Confirmed Cases
12%
Randomized Double-blind
12%
Trial Participants
12%
Group Assignment
12%
Varicella-zoster Virus Infection
12%
Fourth Dose
12%
South Europe
12%
Third Dose
12%
Endpoint Analysis
12%
Medicine and Dentistry
Placebo
100%
Hematopoietic Stem Cell
100%
Stem Cell Transplant
100%
Varicella Zoster Vaccine
100%
Disseminated Herpes Zoster
61%
Attributable Risk
23%
Adverse Event
23%
Vaccine
23%
Hazard Ratio
7%
Transplantation
7%
Polymerase Chain Reaction
7%
Opportunistic Infection
7%
Antivirus Agent
7%
Inactivated Virus Vaccine
7%
Chickenpox
7%
Inactivated Vaccine
7%
Injection Site
7%
Varicella Zoster Virus
7%